China’s FDA joined ICH, Takeda completed new solid dosage plant, the FDA bans imports of Ipca drugs.
Just a month after FDA staff gave a ringing endorsement to Pfizer's biosimilar for Amgen's blockbuster Epogen, the agency rejected the drug.
Scientific progress is leading to effective—but sometimes expensive—new treatments. Learn how value-based contracting could be the solution to pay for these…
Shingrix met its goal in a study examining whether it can protect older adults who previously received Merck’s Zostavax.
The EU's highest court ruled that EU national courts don't need scientific proof to consider a vaccine as defect.
A shareholder campaign demanding change at Mylan has come up short.
Full results from BMS' Opdivo monotherapy trial in first-line lung cancer are finally out—alongside a theory about why that trial came up short.
A federal jury has found that Teva must pay GlaxoSmithKline $235 million in a carve-out patent case over heart drug Coreg.
Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.
Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.
Biopharma and its investors are breathing a sigh of relief on reports of the White House's drug pricing plans.